FDA looks to fund AI/ML-based postmarket surveillance research approach for complex generics

The FDA today issued a funding opportunity announcement seeking to fund work that explores how real-world data sources could couple with artificial intelligence (AI)/machine learning (ML) algorithms to compare clinical outcomes between complex generic and brand-name products. The work could represent early steps toward modernizing one part of FDA’s regulation of this complicated product class.

Fill out the form to read the full article.

Required *

Copy link
Powered by Social Snap